2-Deoxy-D-glucose — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	3	—	—	2004-02
Malignant Prostate Neoplasm	Phase2	Phase 2	1	—	—	2006-11
Malignant Breast Neoplasm	Phase1	Phase 1	1	—	—	2004-02
Malignant Gastric Neoplasm	Phase1	Phase 1	1	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KMT2D Loss-of-function1
2-Deoxy-D-glucose

Clinical trials

Trials with this intervention (3)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00633087	A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer(2-Deoxyglucose)	terminated	Phase 1 / Phase 2	12	Rutgers, The State University of New JerseyOTHER	1	Dec 22, 2023	clinicaltrials
NCT00247403	Safety Study of 2DG With Stereotactic Radiosurgery